Chart pattern: Double Bottom (weekly)
▲ Broken out
Broke on Nov 06, 2026 · measured target $122.00 (+16%). Details →
Nov 4, 6:30 AM ET
Zimmer Biomet Holdings, Inc. reported third quarter 2026 net sales of $2.063 billion, representing a 3.1% reported increase and a 3.7% increase on a constant currency basis. Diluted earnings per share were $1.00, down 13.8%, while adjusted diluted earnings per share were flat at $1.90. Following the broad-based performance, the company raised its full-year 2026 organic constant-currency revenue growth and adjusted EPS guidance.
- Third quarter net sales reached $2.063 billion, up 3.1% on a reported basis.
- Diluted earnings per share were $1.00, compared to $1.16 in the prior year period.
- Adjusted diluted earnings per share were $1.90, matching the prior year period.
- Full-year 2026 adjusted diluted EPS guidance was updated to a range of $8.50 to $8.60.
Read the filing on SEC.gov ↗
Sep 8, 4:30 PM ET
Zimmer Biomet said Kevin Thornal, Group President, Global Businesses and the Americas, will leave the company effective September 30, 2026, as his position is restructured. Gary Campbell, Brian Hatcher and Bradley Kessler were promoted to new roles effective October 1, and the company reiterated its full-year 2026 financial outlook provided on August 5, 2026.
- Kevin Thornal's position is restructured and he departs effective September 30, 2026, with severance under the Restated Executive Severance Plan.
- Thornal's severance is a lump sum of twelve months of base salary plus target annual bonus, plus twelve months of COBRA premiums, conditioned on a general release.
- Gary Campbell becomes President, Americas; Brian Hatcher becomes President, Recon, S.E.T., CMFT, Neuro and Biosurgery; Bradley Kessler becomes President, Americas – Robotics, Technology and Data, all effective October 1.
- The company reiterated its full-year 2026 financial outlook provided on August 5, 2026.
Read the filing on SEC.gov ↗
Aug 5, 6:30 AM ET
Zimmer Biomet reported second-quarter 2026 net sales of $2.177 billion, up 4.8% from the prior year, and diluted earnings per share of $1.03, up 33.8%. The company raised its full-year 2026 reported revenue and adjusted diluted EPS guidance, and adjusted EPS for the quarter was flat at $2.07.
- Q2 net sales of $2.177 billion rose 4.8% reported and 4.0% on an organic constant currency basis.
- Q2 diluted EPS was $1.03, up 33.8%; adjusted diluted EPS was $2.07, consistent with the prior year period.
- 2026 reported revenue change guidance raised to 3.9% to 4.9% from 2.5% to 4.5%; adjusted diluted EPS guidance raised to $8.47 to $8.59 from $8.40 to $8.55.
- Share repurchase expectation increased to up to $1 billion of common stock during fiscal year 2026.
Read the filing on SEC.gov ↗
Jun 29, 4:02 PM ET
Zimmer Biomet signed a new $1.5 billion five-year unsecured revolving credit agreement and a $1.25 billion 364-day unsecured revolving credit agreement, both dated June 26, 2026, with JPMorgan Chase Bank as administrative agent. The company said the borrowings will fund general corporate purposes and terminated its two prior revolving facilities dated June 27, 2025, which had no balance outstanding. The filing describes the new facilities as financing arrangements that carry covenants, including a maximum consolidated indebtedness to EBITDA ratio of 4.5 to 1.0.
- Five-year facility of $1.5 billion matures June 26, 2031, with an uncommitted feature to increase it by up to $750.0 million
- 364-day facility of $1.25 billion matures June 25, 2027
- Both agreements require a consolidated indebtedness to EBITDA ratio of no greater than 4.5 to 1.0
- Prior 2025 facilities were terminated June 26, 2026; about $0.4 million in fees were paid in cash
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.